INCY
Incyte insider trading
Health Care · Heavy selling
Close · Oct 5, 2026
$114.13
+30.8% over 12 months
Share price and insider trades
INCY closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$58.3M
Insiders buying0
Insiders selling10
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Incyte insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $58.3M. 49 of 49 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 111 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 17SEC | Pablo J CagnoniPresident | Sell Plan | 13,985 | $120.49 | $1.7M | -5.3% | — |
| Sep 17SEC | Pablo J CagnoniPresident | Sell Plan | 9,233 | $120.50 | $1.1M | -5.3% | — |
| Aug 20SEC | Pablo J CagnoniPresident | Sell Plan | 10,801 | $125.56 | $1.4M | -9.1% | — |
| Aug 14SEC | Pablo J CagnoniPresident | Sell Plan | 10,803 | $120.04 | $1.3M | -4.9% | — |
| Aug 7SEC | Pablo J CagnoniPresident | Sell Plan | 10,640 | $122.69 | $1.3M | -7.0% | — |
| Aug 7SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 2,207 | $123.99 | $274K | -8.0% | — |
| Aug 4SEC | Pablo J CagnoniPresident | Sell Plan | 15,888 | $119.70 | $1.9M | -4.7% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 14,661 | $119.46 | $1.8M | -4.5% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 6,171 | $119.43 | $737K | -4.4% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 6,055 | $120.43 | $729K | -5.2% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 5,332 | $119.42 | $637K | -4.4% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 4,695 | $119.39 | $561K | -4.4% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 2,864 | $119.40 | $342K | -4.4% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 2,293 | $119.41 | $274K | -4.4% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 2,187 | $119.47 | $261K | -4.5% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 1,643 | $119.51 | $196K | -4.5% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 1,642 | $119.38 | $196K | -4.4% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 326 | $121.69 | $40K | -6.2% | — |
| Aug 4SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 85 | $122.19 | $10K | -6.6% | — |
| Jul 20SEC | Steven H SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 1,877 | $114.73 | $215K | -0.5% | — |
| Jul 20SEC | Mohamed Khairie IssaEvp, Head Of U.S. Commercial | Sell Plan | 1,093 | $115.01 | $126K | -0.8% | — |
| Jul 16SEC | Steven H SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 28,237 | $113.05 | $3.2M | +1.0% | — |
| Jun 8SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 2,639 | $100.00 | $264K | +14.1% | — |
| May 28SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 2,051 | $97.35 | $200K | +17.2% | — |
| May 21SEC | Paul J ClancyDirector | Sell Plan | 15,000 | $94.93 | $1.4M | +20.2% | — |
| Apr 21SEC | Pablo J CagnoniPresident | Sell Plan | 18,667 | $96.50 | $1.8M | +18.3% | — |
| Mar 19SEC | Pablo J CagnoniPresident | Sell Plan | 18,667 | $94.24 | $1.8M | +21.1% | — |
| Feb 23SEC | Pablo J CagnoniPresident | Sell Plan | 18,668 | $100.91 | $1.9M | +13.1% | — |
| Jan 8SEC | Mohamed Khairie IssaEvp, Head Of Us Oncology | Sell Plan | 10,856 | $109.07 | $1.2M | +4.6% | — |
| Jan 7SEC | Steven H SteinEvp & Chief Medical Officer | Sell Plan | 15,634 | $101.70 | $1.6M | +12.2% | — |
| Dec 22SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 2,774 | $100.00 | $277K | +14.1% | — |
| Dec 22SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 600 | $98.25 | $59K | +16.2% | — |
| Dec 18SEC | Michael James MorrisseyEvp, Head Of Tech. Operations | Sell Plan | 53,175 | $97.29 | $5.2M | +17.3% | — |
| Dec 18SEC | Michael James MorrisseyEvp, Head Of Tech. Operations | Sell Plan | 4,323 | $97.26 | $420K | +17.3% | — |
| Dec 18SEC | Michael James MorrisseyEvp, Head Of Tech. Operations | Sell Plan | 833 | $97.42 | $81K | +17.2% | — |
| Dec 12SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 5,553 | $95.58 | $531K | +19.4% | — |
| Dec 12SEC | Patrick A MayesEvp & Chief Scientific Officer | Sell Plan | 255 | $94.94 | $24K | +20.2% | — |
| Dec 3SEC | Steven H SteinEvp & Chief Medical Officer | Sell Plan | 20,105 | $102.51 | $2.1M | +11.3% | — |
| Dec 3SEC | Steven H SteinEvp & Chief Medical Officer | Sell Plan | 2,559 | $102.96 | $263K | +10.8% | — |
| Nov 25SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 600 | $103.00 | $62K | +10.8% | — |
| Nov 25SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 169 | $102.00 | $17K | +11.9% | — |
| Nov 19SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 278 | $104.36 | $29K | +9.4% | — |
| Nov 12SEC | Herve HoppenotDirector | Sell Plan | 187,500 | $105.46 | $19.8M | +8.2% | — |
| Nov 7SEC | Steven H SteinEvp & Chief Medical Officer | Sell Plan | 5,233 | $102.20 | $535K | +11.7% | — |
| Nov 6SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 598 | $101.36 | $61K | +12.6% | — |
| Nov 5SEC | Lee HeesonEvp, Head Of Incyte Intl | Sell Plan | 3,074 | $94.02 | $289K | +21.4% | — |
| Oct 17SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 277 | $85.13 | $24K | +34.1% | — |
| Oct 6SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 3,501 | $85.54 | $299K | +33.4% | — |
| Oct 6SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 599 | $87.65 | $53K | +30.2% | — |
Insiders at Incyte
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Herve HoppenotDirector | — | $19.8M | Dec 10, 2025 | — |
| Pablo J CagnoniPresident | — | $14.1M | Sep 17, 2026 | — |
| Steven H SteinCmo & Head Of Late-Stage Dev. | — | $7.9M | Jul 20, 2026 | — |
| Patrick A MayesEvp & Chief Scientific Officer | — | $6.6M | Aug 7, 2026 | — |
| Michael James MorrisseyEvp, Head Of Tech. Operations | — | $5.7M | Feb 4, 2026 | — |
| Paul J ClancyDirector | — | $1.4M | Oct 2, 2026 | — |
| Mohamed Khairie IssaEvp, Head Of U.S. Commercial | — | $1.3M | Jul 20, 2026 | — |
| Thomas TrayPrincipal Accounting Officer | — | $879K | Jul 20, 2026 | — |
| Sheila A. DentonGeneral Counsel | — | $465K | Nov 19, 2025 | — |
| Lee HeesonEvp, Head Of Incyte Intl | — | $289K | Feb 4, 2026 | — |
| Edmund HarriganDirector | — | — | Oct 2, 2026 | — |
| Baker Bros. Advisors LpDirector | — | — | Oct 2, 2026 | — |
| David H GardnerEvp, Chief Strategy Officer | — | — | Sep 24, 2026 | — |
| Ramitpal K BasiEvp, Human Resources | — | — | Aug 27, 2026 | — |
| William MeuryCEO | — | — | Jul 20, 2026 | — |
| Richard A. HoffmanGeneral Counsel | — | — | Jul 20, 2026 | — |
| Otis W BrawleyDirector | — | — | Jun 10, 2026 | — |
| Jean Jacques BienaimeDirector | — | — | Jun 10, 2026 | — |
| Jacqualyn A FouseDirector | — | — | Jun 10, 2026 | — |
| Katherine A HighDirector | — | — | Jun 10, 2026 | — |
| Suketu UpadhyayCFO | — | — | May 6, 2026 | — |
| Matteo TrottaEvp, Gm, Dermatology Us | — | — | Mar 26, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about INCY insiders
Are Incyte insiders buying INCY stock?
In the past 12 months, 0 insiders reported open-market purchases of INCY worth $0.
Are Incyte insiders selling INCY stock?
10 insiders reported sales worth $58.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.